Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Edgewise Therapeutics (Nasdaq: EWTX) announced that Kevin Koch, Ph.D., President and CEO, will present at the 44th Annual J.P.
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) announced that Kevin Koch, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 8:15 am PT (11:15 am ET). The presentation will be webcast live and available for replay for a limited time on the company's Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.
Details
News Market Reaction – EWTX
On Jan 6, the day this news came out, EWTX closed 2.67% below the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference date
- January 13, 2026
- J.P. Morgan Healthcare Conference presentation date
- Presentation time PT
- 8:15 am PT
- Scheduled EWTX presentation slot
- Q3 2025 net loss
- $40.7 million
- Net loss reported in Q3 2025 10-Q
- Cash & securities
- $563.3 million
- Cash, cash equivalents and marketable securities as of Sep 30, 2025
- Operating expenses
- $46.9 million
- Q3 2025 operating expenses
- R&D expense
- $37.5 million
- Q3 2025 research and development expense
- Shares outstanding
- 105,761,949
- Shares outstanding as of Sep 30, 2025
- Market cap
- $2,514,375,308
- Pre-news market capitalization
Historical Context
-
Positive Phase 2 EDG-7500 data with favorable interim safety in HCM.
-
Equity inducement grant for new hire under 2024 Inducement Equity Plan.
-
Appointment of commercial executive Christopher Martin to Board of Directors.
-
Inducement stock options and RSUs granted to incoming CFO Michael Nofi.
-
Appointment of new CFO and retirement of prior CFO with planned transition.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Event Details:
Date: Tuesday, January 13, 2026
Time: 8:15 am PT (11:15 am ET)
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-january-13-2026-302653408.html
SOURCE Edgewise Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.